Sumatriptan-Associated Ischemic Colitis: Case report and Review of the Literature and FAERS
- 372 Downloads
Background and Aims
Ischemic colitis (IC) is being increasingly recognized, although specific etiological causes are observed in a minority of patients. While several drugs have been associated with IC, most remain anecdotal reports. We recently treated a patient with IC thought to be related to sumatriptan for migraines, and performed a literature review along with a review of the FDA Adverse Event Reporting System (FAERS) database to identify additional cases.
A MEDLINE/PubMed literature review was conducted using standard IC search terms to identify published cases of sumatriptan and other related “triptan” drug causes of IC. In addition, through a Freedom of Information Act request, we reviewed the adverse gastrointestinal events linked to sumatriptan contained in the FAERS database for the 5-year period 12 March 2008–11 March 2013, in order to determine whether unpublished cases might exist. Our case of IC was analyzed using a causality assessment tool initially developed for use in cases of alosetron (a 5-HT3 receptor antagonist)-related IC.
Five published reports (containing a total of seven patients) describing sumatriptan-associated IC in the English language literature were found and reviewed. Another four published reports of related 5-HT1 receptor agonists causing IC (razitriptan n = 1 and naratriptan n = 3) were also analyzed. Among spontaneous reports of possible IC contained in the FAERS database for sumatriptan, there were 19 adverse events coded as “ischemic colitis” and another six coded as “intestinal ischemia” over a 5-year period ending March 2013, but clinical details were lacking. Similarly, five reports of possible IC from FAERS were mentioned in an earlier published report from the late 1990s. All of the published case reports of sumatriptan and related drugs were deemed to have the classic clinical findings and all recovered. There was one instance of possible recurrent IC symptoms in one patient re-exposed to sumatriptan, but not in another. We found that the IC scoring system developed for alosetron was applicable in our sumatriptan case.
Among drug-related causes of IC, sumatriptan joins a growing list of agents with literature reports supported by the finding of suspected cases of IC in the FAERS database. However, the true incidence of IC due to sumatriptan, as well as other causes, cannot be accurately determined because of the likelihood of under-reporting. The structured IC scoring system appears to be applicable for drug-related as well as other etiological causes of IC.
KeywordsMigraine Irritable Bowel Syndrome Sumatriptan Rizatriptan Triptan
The authors thank Adrien Mazer, MD (Department of Medicine) for his assistance with managing the patient, and Bhaskar Kallakury, MD (Department of Pathology) for his help in preparing the pathology photomicrographs.
Thuc Quyen Nguyen drafted the manuscript. James H. Lewis conceived, drafted, and critically revised the manuscript.
No sources of funding were used to assist in the preparation of this study. Thus Quyen Nguyen and James H. Lewis have no conflicts of interest that are directly relevant to the content of this study.
- 28.Deana DG, Dean PJ. Reversible ischemic colitis in young women in association with oral contraceptive use. Am J Surg Pathol 19 (1995): :454- 62.Google Scholar
- 32.Salk A, Stobaugh DJ, Deepak P, Ehrenpreis ED. Ischemic colitis with type 1 interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the Food and Drug Administration Adverse Event Reporting System and review of the literature. Ann Pharmacother. 2013;47:537–42.PubMedCrossRefGoogle Scholar
- 39.Ringle Y, Wilson J, D’Agostino R, Lewis JH. Development and validation of an ischemic colitis clinical diagnosis assessment instrument. Gastroenterology 2005;128.4 (Suppl 2):A467.Google Scholar
- 40.Imitrex tablets prescribing information, 2012. GlaxoSmithKline Research Triangle Park, NC 27709. http://us.gsk.com/products/assets/us_imitrex_tablets.pdf Accessed 7 Dec 2013.
- 41.Amerge (naratriptan hydrochloride) tablets prescribing information, October 2013. GlaxoSmithKline Research Triangle Park, NC 27709. http://us.gsk.com/products/assets/us_amerge.pdf. Accessed 7 Dec 2013.
- 42.Maxalt (rizatriptan benzoate) prescribing information, January 2013. Merck & Co. Whitehouse Station, NJ 08889. http://www.merck.com/product/usa/pi_circulars/m/maxalt/maxalt_pi.pdf. Accessed 7 Dec 2013.
- 43.Relpax (eletriptan hydrobromide) tablets prescribing information, May 2008; Roerig Division of Pfizer, NY,NY 10017. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=986dc112-b97b-44a3-bfaf-074f906f8bb2. Accessed 7 Dec 2013.
- 44.Axert (almotriptan malate) tablets prescribing information, April 2011; Ortho-McNeil Neurologics, Titusville, NJ 08560. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b13ba9bf-1661-456a-8eae-6d110ea08c94. Accessed 7 Dec 2013.
- 45.Frova (frovatriptan succinate) prescribing information, April 2007; Endo Pharmaceuticals, Inc. 100 Endo Blvd, Chadds Ford, PA 19317. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=294d60f3-005b-40d9-a404-cdd77f62b820. Accessed 7 Dec 2013.
- 46.Zomig (zolmitriptan) prescribing information, September 2012; AstraZeneca/Impax Pharmaceuticals, Hawward, CA 94544. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=294d60f3-005b-40d9-a404-cdd77f62b820. Accessed 7 Dec 2013.
- 47.Personal communication, JP Nicandro. Data on file with Prometheus Laboratories, San Diego, CA.Google Scholar